Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: an open-label, randomised phase 3 trialJean-Pascal Machiels, Paul M. Clément, Igor Lifirenko et al.|The Lancet Oncology|2011Cited by 242
An open-label, randomized, phase III trial of zalutumumab, a human monoclonal EGF receptor (EGFr) antibody, versus best supportive care, in patients with noncurable squamous cell carcinoma (SCCHN) of the head and neck who have failed standard platinum-based chemotherapy (ZALUTE).J. H. Machiels, Paul M. Clément, S. Subramanian et al.|Journal of Clinical Oncology|2010Cited by 13